Nls Pharmaceutics Ag (NLSPW)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Nls Pharmaceutics Ag Borsa (NLSPW) Ultime notizie

Nls Pharmaceutics Ag (NLSPW)

Nls Pharmaceutics Ag Borsa (NLSPW) Ultime notizie

NLS Pharmaceutics and Kadimastem eye January merger - Investing.com

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire

NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India

NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria

NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India

NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com UK

NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire

NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan

NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com

NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Australia

NLS Pharmaceutics sets terms for $1M private placement - Investing.com

NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online

NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa

NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria

NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com

NLS Pharmaceutics reveals promising preclinical data - Investing.com

NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire

NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks

NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire

NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan

NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks

NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com

500: Something went wrong - Investing.com India

Kadimastem Ltd. Faces Financial Uncertainty - TipRanks

NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks

NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance

NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India

NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK

NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - Seeking Alpha

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - AccessWire

NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com Nigeria

NLSP stock touches 52-week low at $4 amid sharp annual decline By Investing.com - Investing.com South Africa

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire

NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance

NLS Pharmaceutics announces expected compliance with Nasdaq listing rules - TipRanks

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - AccessWire

NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks

NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks

NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com

NLS Pharmaceutics Shareholders Approve Agenda - TipRanks

NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com

NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks

Simile a NLSPW